Hisham Abdel-Azim (Loma Linda, CA, USA) and colleagues presented results from the multicentre phase 2 EndRAD trial (NCT03509961) examining myeloablative non-total-body-irradiation conditioning regimens for allogeneic HSCT in patients (aged 1 year to <31 years) with B-ALL at lower relapse risk. 51 patients underwent HSCT and, at a median follow-up of 2·3 years (range 0·2-6·0), the primary endpoint of 2-year event-free survival (EFS) was 76·3% (95% CI 61·1-86·1). Transplant-related mortality in the first 100 days after HSCT was 2%. Non-relapse mortality (NRM) was 12% (n=6) and occurred predominantly in older children, with four aged 14 years or older. Chronic graft-versus-host disease occurred in 13 (25%) of 51 patients.